Alex Denner (Getty Images)
November 6, 2020 09:44 AM ESTUpdated 10:12 AM
People

Two years af­ter a re­buffed ac­tivist at­tack, Alex Den­ner fi­nal­ly gets his seat on Iron­wood's board

Jason Mast

Editor

Faced with an in­sur­gency from the ac­tivist in­vestor Alex Den­ner in 2018, Iron­wood Phar­ma­ceu­ti­cals mount­ed a vo­cal and ul­ti­mate­ly suc­cess­ful cam­paign to keep the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times